Thursday, April 22, 2021 3:24:23 PM
KANSAS STATE UNIVERSITY
https://www.cocrystalpharma.com/
update 04-22-21
New peer reviews of COVID-19 preprints from the MIT Press journal RAPID REVIEWS COVID-19
THE MIT PRESS
https://www.eurekalert.org/pub_releases/2020-09/tmp-npr090420.php
===============================================================
https://www.eurekalert.org/pub_releases/2020-08/ksu-nps080320.php
[-chart]media.eurekalert.org/multimedia_prod/pub/web/239228_web.jpg[/chart]
MANHATTAN, KANSAS -- Yunjeong Kim and Kyeong-Ok "KC" Chang,
virologists in the College of Veterinary Medicine at Kansas State University,
have published a study showing a possible therapeutic
treatment for COVID-19.
Pathogenic coronaviruses are a major threat to global public health,
as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV;
Middle East respiratory syndrome coronavirus, known as MERS-CoV;
and the newly emerged SARS-CoV-2, the virus that causes COVID-19 infection.
The study, "3C-like protease inhibitors block coronavirus replication
in vitro and improve survival in MERS-CoV-infected mice,"
appears in the Aug. 3 issue of the prestigious medical journal Science Translational Medicine.
It reveals how small molecule protease inhibitors show potency against human coronaviruses.
These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
"Vaccine developments and treatments are the biggest targets in
COVID-19 research, and treatment is really key,"
said Chang, professor of diagnostic medicine and pathobiology.
"This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target."
The study demonstrates that this series of optimized coronavirus
3CLpro inhibitors blocked replication of the human coronaviruses
MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS.
These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim have been using National Institutes of Health grants
to develop antiviral drugs to treat MERS and human norovirus infections.
Their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
"The work that this group of collaborators has been doing on
antivirals and inhibitors for SARS and MERS at K-State for a number
of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics,"
said Peter K. Dorhout, vice president for research at K-State.
Co-collaborators on the research include teams lead by Bill Groutas
at Wichita State University,
Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
"Drs. Groutas,
Perlman and
Lovell brought decades of experience to our research team,"
Chang said.
"We would not have been able to come this far without important collaborations with our colleagues at other institutions."
"Getting things published right now is very important for the scientific community," Kim said. "I think we are adding valuable information to the antiviral field."
###
The new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. K-State Innovations Partners handles commercial technology licensing for the university.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy
of news releases posted to EurekAlert! by contributing institutions
or for the use of any information through the EurekAlert system.
Recent COCP News
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:43 PM
- Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 02:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:40 PM
- Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 01:00:21 PM
- Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:01:00 PM
- Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:00:18 PM
- Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
- Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 12:00:50 PM
- Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 08/14/2023 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM